JNJ - Johnson & Johnson

NYSE - Nasdaq Real-time price. Currency in USD
142.23
+1.78 (+1.27%)
As of 1:28PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close140.45
Open141.25
Bid141.95 x 900
Ask141.96 x 800
Day's range141.00 - 142.31
52-week range120.11 - 148.99
Volume2,866,728
Avg. volume6,588,884
Market cap377.629B
Beta (3Y monthly)0.73
PE ratio (TTM)26.36
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.80 (2.71%)
Ex-dividend date2019-05-24
1y target estN/A
Trade prices are not sourced from all markets
  • Bloombergyesterday

    Billions at Stake in Opioid Suits, But It's No Tobacco Windfall

    (Bloomberg) -- An Oklahoma case, the first of more than 1,600 lawsuits filed by U.S. state and local governments against opioid makers to go to trial, could serve as a key benchmark for governments hoping to recoup costs associated with the public health crisis.However, verdicts and legal settlements resulting from the litigation are likely to be smaller than the 1998 global settlement with tobacco companies and won’t significantly affect government budgets, according to Fitch Ratings.The tobacco settlement with 46 states compensated them with more than $200 billion for decades of tobacco-related health-care costs, but wasn’t enough to alter state and local government credit quality, according to Fitch. The opioid epidemic has taken place over a shorter time span, and hasn’t resulted in as many deaths, according to Marcy Block, a Fitch analyst.“It’s severe, but it’s less if you think about the amount of deaths through tobacco usage,” Block said.Ten TimesMore than 47,000 Americans died from opioid overdoses in 2017, including heroin and fentanyl, a synthetic opioid, according to the National Institute on Drug Abuse. Cigarette smoking is responsible for ten times as many deaths annually, according to the Centers for Disease Control and Prevention.Oklahoma sued Johnson & Johnson, Purdue Pharma LP and Teva Pharmaceutical Industries Ltd. in 2017, alleging the companies deceived the public by overstating the benefits of their drugs while downplaying the risk of addiction. Teva in May agreed to pay $85 million to resolve the suit. Purdue Pharma, the maker of OxyContin, agreed in March to pay $270 million.Read more about how opioid makers are getting squeezed as cities try to form a negotiating groupThe opioid litigation could cost the pharmaceutical industry between $5 billion and $50 billion, based on the 1998 tobacco deal and costs of the abuse epidemic, according to Bloomberg Intelligence analyst Holly Froum. Oklahoma is seeking at least $10 billion in damages and penalties for current and future outlays from Johnson & Johnson.“The depth of evidence against the opioid manufacturers, including any potential evidence of fraudulent marketing, will be a key determinant not only of how this case is decided, but the thousands of additional cases against the industry, “ wrote Rachel Barkley, a senior vice president at Loop Capital Markets earlier this month.“Additionally, the size of any settlement would likely serve as a benchmark in future cases,” she said.Securtitized ProceedsStates and local governments issued tens of billions of dollars in muni bonds backed by the tobacco settlement and some used that money to plug budget gaps. The securities are repaid with the money they receive each year from cigarette companies under the settlement. The amount of the payments is based on annual cigarette shipments. There are currently $85 billion of tobacco bonds outstanding, including debt issued to refinance previously issued securities.At least 42 states and more than 1,900 municipalities have sued opioid manufactures and distributors, blaming them for creating a national public-health crisis and demanding billions of dollars in damages.A U.S. federal judge in Cleveland is overseeing opioid litigation brought by U.S. cities and counties and has set two trials for October. The scope of the litigation could result in a global settlement that mimics the resolution to the tobacco cases in the 1990s.The CDC estimates that the total “economic burden” of prescription opioid misuse alone in the U.S. is $78.5 billion a year, including the costs of health care, lost productivity, addiction treatment and criminal justice involvement.Factoring the economic value of lives lost, the White House’s Council of Economic Advisers estimated the costs of the epidemic in 2015 totaled $504 billion.Related: States Are Suing Opioid Makers But Their Pensions Embrace ThemTo contact the reporter on this story: Martin Z. Braun in New York at mbraun6@bloomberg.netTo contact the editors responsible for this story: James Crombie at jcrombie8@bloomberg.net, Michael B. Marois, Shannon D. HarringtonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Big Drugmakers That May Tread the M&A Path After Pfizer
    Zacksyesterday

    Big Drugmakers That May Tread the M&A Path After Pfizer

    There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

  • Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
    Zacks3 days ago

    Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $139.44, moving -0.46% from the previous trading session.

  • J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
    Zacks3 days ago

    J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

    J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

  • Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion
    Zacks6 days ago

    Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion

    Dassault's acquisition of Medidata (MDSO) to close by 2019-end.

  • Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
    Zacks6 days ago

    Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

    Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

  • Barrons.com7 days ago

    Johnson & Johnson Made the Right Call in Fighting Oklahoma Over Opioids, Analyst Says

    Teva Pharmaceutical and Purdue Pharma both settled with Oklahoma over allegations they contributed to the state’s opioid crisis.

  • Barrons.com7 days ago

    Johnson & Johnson and Cisco Directors Are Buying Up Stock

    Lockheed CEO Marillyn Hewson made the first insider purchase of J&J stock this year, while Northrop Grumman Chairman Wes Bush bought up Cisco stock.

  • J&J, Colgate ordered to pay nearly $10 million in California talc cancer case
    CNBC8 days ago

    J&J, Colgate ordered to pay nearly $10 million in California talc cancer case

    Plaintiff Patricia Schmitz will be awarded $4.8 million in damages from each company.

  • Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
    Zacks9 days ago

    Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $139.78, moving +0.55% from the previous trading session.

  • How Analysts Rate Tandem Diabetes Care and Insulet
    Market Realist10 days ago

    How Analysts Rate Tandem Diabetes Care and Insulet

    Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?Evolving insulin delivery landscapeUntil the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson

  • Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May
    Motley Fool10 days ago

    Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May

    The biopharma company started several new clinical trials and enjoyed success in others since the start of the calendar year.

  • Why Investors Should Keep an Eye on the Oklahoma Opioid Trial Against Johnson & Johnson
    Motley Fool13 days ago

    Why Investors Should Keep an Eye on the Oklahoma Opioid Trial Against Johnson & Johnson

    The case, which is premised on a unproven legal theory, could impact the course of future opioid litigation.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper
    Zacks13 days ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper

  • Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
    Zacks13 days ago

    Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

    Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

  • Barrons.com13 days ago

    Teva and J&J Stocks Were Hit by Opioid Worries. What Could Come Next.

    A federal judge in Ohio is pushing for a settlement that could sweep in more than a thousand separate opioid lawsuits.

  • Should You Be Holding Johnson & Johnson (NYSE:JNJ)?
    Simply Wall St.13 days ago

    Should You Be Holding Johnson & Johnson (NYSE:JNJ)?

    Johnson & Johnson (NYSE:JNJ) is a company with exceptional fundamental characteristics. Upon building up an investment...

  • Barrons.com13 days ago

    How Funds That Chase the Hottest Stocks Can Still Lag Behind

    How often momentum funds adjust their holdings, and when they do so, can make a big difference to their performance. A rebalancing in May came at just the wrong time for one momentum ETF.

  • Celgene & Acceleron's BLA for Luspatercept Accepted by FDA
    Zacks14 days ago

    Celgene & Acceleron's BLA for Luspatercept Accepted by FDA

    Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.

  • Top Stock Reports for Johnson & Johnson, Chevron & Adobe
    Zacks14 days ago

    Top Stock Reports for Johnson & Johnson, Chevron & Adobe

    Top Stock Reports for Johnson & Johnson, Chevron & Adobe

  • Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
    Zacks15 days ago

    Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

    In the latest trading session, Johnson & Johnson (JNJ) closed at $134.46, marking a +0.55% move from the previous day.

  • Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
    Zacks15 days ago

    Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

  • Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
    Zacks21 days ago

    Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $132.12, moving +0.6% from the previous trading session.

  • Barrons.com21 days ago

    Johnson & Johnson’s Stock Slide From Opioid Trial Worries Is ‘Overdone’

    Johnson & Johnson stock has slumped as the company’s civil trial over its alleged role in the opioid crisis in Oklahoma has gotten under way. But analysts say worries about its opioid liabilities are overblown.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes